Jeger RV, Farah A, Ohlow MA, et al. - Given that drug-coated balloons (DCBs) are non-inferior to drug-eluting stents (DESs), in terms of clinical outcome up to 12 months, in patients with de-novo coronary small vessel disease, however, data beyond 1 year is sparse, and therefore researchers undertook this prespecified long-term follow-up of a multicentre, randomised, open-label, non-inferiority trial to assess the long-term efficacy as well as safety of DCBs concerning clinical endpoints in an all-comer population receiving percutaneous coronary intervention. Participants were selected from 14 clinical sites in Germany, Switzerland, and Austria. Using randomization 1:1, patients with de-novo lesions in coronary vessels < 3 mm and an indication for percutaneous coronary intervention were managed with DCB or second-generation DES. In DCB vs DES patients, rates of all-cause mortality were very similar. Albeit not significant, numerically lower rates of probable or definite stent thrombosis and major bleeding were noted in DCB vs DES. Findings are indicative of a maintained efficacy as well as safety of DCB compared with DES in the treatment of de-novo coronary small vessel disease up to 3 years.